These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 10226676)

  • 41. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database.
    Olsen KR; Bilde L; Juhl HH; Kjaer NT; Mosbech H; Evald T; Rasmussen M; Hiladakis H
    Eur J Health Econ; 2006 Dec; 7(4):255-64. PubMed ID: 16816946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paying Low-Income Smokers to Quit? The Cost-Effectiveness of Incentivizing Tobacco Quit Line Engagement for Medicaid Recipients Who Smoke.
    Mundt MP; Baker TB; Fraser DL; Smith SS; Piper ME; Fiore MC
    Value Health; 2019 Feb; 22(2):177-184. PubMed ID: 30711062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Smoking Cessation Support Services at Community Pharmacies in the UK: A Systematic Review.
    Peletidi A; Nabhani-Gebara S; Kayyali R
    Hellenic J Cardiol; 2016; 57(1):7-15. PubMed ID: 26856195
    [No Abstract]   [Full Text] [Related]  

  • 44. Economics of smoking cessation.
    Parrott S; Godfrey C
    BMJ; 2004 Apr; 328(7445):947-9. PubMed ID: 15087348
    [No Abstract]   [Full Text] [Related]  

  • 45. Cost-effectiveness analysis of a family physician delivered smoking cessation program.
    Buck DJ; Richmond RL; Mendelsohn CP
    Prev Med; 2000 Dec; 31(6):641-8. PubMed ID: 11133329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
    Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
    Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of an intensive telephone-based intervention for smoking cessation.
    Smith MW; An LC; Fu SS; Nelson DB; Joseph AM
    J Telemed Telecare; 2011; 17(8):437-40. PubMed ID: 22025745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The affliction of addiction.
    Carlisle D
    Nurs Times; 2002 Oct 1-8; 98(40):22-5. PubMed ID: 12382438
    [No Abstract]   [Full Text] [Related]  

  • 49. Developments: Bright sparks.
    Health Serv J; 2009 Sep; 119(6175):30-1. PubMed ID: 19877351
    [No Abstract]   [Full Text] [Related]  

  • 50. Cost-effectiveness of a smoking cessation program after myocardial infarction.
    Krumholz HM; Cohen BJ; Tsevat J; Pasternak RC; Weinstein MC
    J Am Coll Cardiol; 1993 Nov; 22(6):1697-702. PubMed ID: 8227841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The costs of benefits: smoking cessation and health care expenditures.
    Warner KE
    Am J Health Promot; 2003; 18(2):123-4, ii. PubMed ID: 14621406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A dynamic, modifiable model for estimating cost-effectiveness of smoking cessation interventions in pregnancy: application to an RCT of self-help delivered by text message.
    Jones M; Smith M; Lewis S; Parrott S; Coleman T
    Addiction; 2019 Feb; 114(2):353-365. PubMed ID: 30347119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intensive smoking cessation efforts cost-effective.
    Marwick C
    JAMA; 1996 Oct 23-30; 276(16):1291. PubMed ID: 8861975
    [No Abstract]   [Full Text] [Related]  

  • 54. Going Once, Going Twice: Using Willingness-to-Accept Auctions to Promote Smoking Cessation.
    Quisenberry AJ; Shaw S; Ferketich AK; Corrigan JR
    Nicotine Tob Res; 2020 Aug; 22(9):1632-1635. PubMed ID: 32304211
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successes and new emerging challenges in tobacco control: addressing the vector.
    Mackay JM; Bettcher DW; Minhas R; Schotte K
    Tob Control; 2012 Mar; 21(2):77-9. PubMed ID: 22345225
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events.
    Keeney E; Welton NJ; Stevenson M; Dalili MN; López-López JA; Caldwell DM; Phillippo DM; Munafò MR; Thomas KH
    Value Health; 2021 Jun; 24(6):780-788. PubMed ID: 34119075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Payers see the light on smoking cessation programs.
    Dis Manag Advis; 2005 Jun; 11(6):61-5. PubMed ID: 16060294
    [No Abstract]   [Full Text] [Related]  

  • 58. Budgetary impact of varenicline in smoking cessation in the United Kingdom.
    Taylor DC; Chu P; Rosen VM; Baker CL; Thompson D
    Value Health; 2009; 12(1):28-33. PubMed ID: 18637141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A cost-effectiveness analysis of the first federally funded antismoking campaign.
    Xu X; Alexander RL; Simpson SA; Goates S; Nonnemaker JM; Davis KC; McAfee T
    Am J Prev Med; 2015 Mar; 48(3):318-25. PubMed ID: 25498550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Promoting smoking cessation in Pakistani and Bangladeshi men in the UK: pilot cluster randomised controlled trial of trained community outreach workers.
    Begh RA; Aveyard P; Upton P; Bhopal RS; White M; Amos A; Prescott RJ; Bedi R; Barton P; Fletcher M; Gill P; Zaidi Q; Sheikh A
    Trials; 2011 Aug; 12():197. PubMed ID: 21854596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.